These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes. Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689 [TBL] [Abstract][Full Text] [Related]
4. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB. Bavinger JC; Yu Y; VanderBeek BL Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260 [TBL] [Abstract][Full Text] [Related]
5. Leuconostoc as a Cause of Endophthalmitis Post-intravitreal Injection of Ranibizumab. Damasceno NP; Horowitz SA; Damasceno EF Ocul Immunol Inflamm; 2016; 24(1):118-9. PubMed ID: 24749654 [TBL] [Abstract][Full Text] [Related]
6. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection. Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794 [TBL] [Abstract][Full Text] [Related]
7. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400 [TBL] [Abstract][Full Text] [Related]
8. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia. Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840 [TBL] [Abstract][Full Text] [Related]
9. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA; Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087 [TBL] [Abstract][Full Text] [Related]
17. Clostridium sordellii endophthalmitis after suture removal from a corneal transplant. Zink JM; Singh-Parikshak R; Sugar A; Johnson MW Cornea; 2004 Jul; 23(5):522-3. PubMed ID: 15220740 [TBL] [Abstract][Full Text] [Related]
18. Severe Salceanu SO; Levy S; Cunningham R; Frimpong-Ansah K Indian J Ophthalmol; 2017 Nov; 65(11):1249-1251. PubMed ID: 29133669 [TBL] [Abstract][Full Text] [Related]
19. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA Retina; 2013; 33(7):1407-16. PubMed ID: 23492945 [TBL] [Abstract][Full Text] [Related]